Publications by authors named "Atsushi Hamamura"
Article Synopsis
- - A 63-year-old man with adult T-cell leukemia-lymphoma received a bone marrow transplant from an unrelated donor and was later diagnosed with invasive pulmonary aspergillosis (IPA) 17 days post-transplant.
- - He initially improved with treatment using liposomal amphotericin B, but was switched to voriconazole due to worsening kidney function, and later experienced neurological issues.
- - The patient passed away on day 62, with an autopsy revealing fungal infection in the lungs and a ruptured cerebral aneurysm, emphasizing the need for careful monitoring of transplant patients for fungal-related complications.
Article Synopsis
- Caplacizumab, a therapy for immune-mediated thrombotic thrombocytopenic purpura (iTTP), shows benefits in achieving quicker platelet counts but is linked to slower recovery of ADAMTS13 activity.
- A study compared acute iTTP patients treated with and without caplacizumab, highlighting that those on caplacizumab took longer to normalize ADAMTS13 activity, with significant differences in inhibitor levels and antibody titers.
- The findings suggest that while caplacizumab helps improve platelet counts faster, it may delay the recovery of ADAMTS13 due to fewer plasma exchanges and later administration of rituximab.
An 18-year-old man underwent allogenic bone marrow transplantation (BMT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Ph+ALL relapsed 3 months after the first BMT, and the patient underwent a second BMT. However, Ph+ALL relapsed 4 months after the second BMT, and he received a haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) from his father.
View Article and Find Full Text PDFArticle Synopsis
- CAR T-cell therapy has significantly changed the treatment landscape for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL), showing promising safety and effectiveness in a recent study.
- In a study of 21 patients, 85.7% experienced cytokine release syndrome (CRS), with a 61.9% complete response rate at 3 months and notable survival rates at the 6-month follow-up.
- Despite 38.1% of patients having comorbidities potentially affecting treatment eligibility, these did not significantly impact response rates or adverse events, indicating the therapy's efficacy even in real-world settings.
This prospective phase I trial aimed to determine the recommended dose of 3-day total marrow and lymphoid irradiation (TMLI) for a myeloablative conditioning regimen by increasing the dose per fraction. The primary end-point of this single-institution dose escalation study was the recommended TMLI dose based on the frequency of dose-limiting toxicity (DLT) ≤100 days posthematopoietic stem cell transplantation (HSCT); a 3 + 3 design was used to evaluate the safety of TMLI. Three dose levels of TMLI (14/16/18 Gy in six fractions over 3 days) were set.
View Article and Find Full Text PDFArticle Synopsis
- Late-onset noninfectious pulmonary complications (LONIPC) significantly contribute to health issues in patients after allogeneic hematopoietic stem cell transplantation (HSCT).
- A study over 10.3 years involving 167 long-term HSCT survivors found a consistent decline in lung function measurements, such as vital capacity and forced expiratory volume.
- Restrictive lung function impairment emerged as a critical risk factor for increased mortality, indicating that lung function decline affects overall survival independently of LONIPC.
The impact of the killer immunoglobulin-like receptor (KIR)-ligand mismatch between donor and recipient in hematopoietic stem cell transplantation is controversial. Recently, it has been suggested that their effect on cord blood transplantation (CBT) differs among types of mismatched KIR-ligand and graft-versus-host disease (GVHD) prophylaxis. To investigate their role in acute myeloid leukemia (AML), mismatch of KIR2DL1, KIR3DL1, and KIR3DL2-ligand (HLA-C2, Bw4, and A3/11) were retrospectively assessed in patients undergoing CBT with GVHD prophylaxis comprising a calcineurin inhibitor plus methotrexate (CNI/MTX) or mycophenolate mofetil (CNI/MMF).
View Article and Find Full Text PDFTherapy-related myelodysplastic syndromes (t-MDS) are generally progressive and associated with poorer outcomes than de novo MDS (d-MDS). To evaluate the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for t-MDS, we conducted a propensity score matched-pair analysis of patients with t-MDS and d-MDS using a nationwide database. A total of 178 patients with t-MDS underwent allo-HSCT between 2001 and 2018, and 178 out of 3123 patients with d-MDS were selected.
View Article and Find Full Text PDF